Internal Medicine, Infectious Disease · Terre Haute, IN
NPI
1508974189
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
315 E Davis Dr
Terre Haute, IN, 47802
Phone (812) 645-3472
Groups this clinician bills Medicare through
Medicare paid, 2024
$636K
8,106 services
Medicare patients, 2024
1,070
Average age 74
Drug cost, 2024
$2.8M
7,224 prescriptions
Company payments, 2025
$2,539
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Anwer Jaffri was code 99232 (hospital e&m - subsequent), 4,236 times for 767 patients. In total Anwer Jaffri billed 8,106 services in 31 codes, and Medicare paid $636K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-10-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 4,236 | 767 | $57.93 | $245K |
| 99213 Office E&M - Established | Office | 1,174 | 432 | $62.80 | $74K |
| 99223 Hospital E&M - Initial | Facility | 839 | 672 | $126.79 | $106K |
| 99231 Hospital E&M - Subsequent | Facility | 288 | 69 | $35.96 | $10K |
| 99214 Office E&M - Established | Office | 250 | 158 | $90.95 | $23K |
| 99222 Hospital E&M - Initial | Facility | 187 | 171 | $95.03 | $18K |
| 29581 Musculoskeletal | Office | 89 | 17 | $80.04 | $7,124 |
| 99309 SNF E&M | Facility | 78 | 35 | $62.32 | $4,861 |
| 36589 Venous Catheter Insertion | Office | 70 | 69 | $116.77 | $8,174 |
| 99203 Office E&M - New | Office | 65 | 65 | $74.30 | $4,830 |
| 99291 Critical Care E&M | Facility | 38 | 36 | $156.20 | $5,936 |
| 99204 Office E&M - New | Office | 31 | 31 | $107.42 | $3,330 |
| 99442 Telephone Services | Office | 23 | 18 | $66.64 | $1,533 |
By year: 2022 $671K for 129,889 services; 2023 $696K for 40,483 services; 2024 $636K for 8,106 services.
Medicare prescription drug claims, 2024
In 2024, the drug Anwer Jaffri prescribed most often to Medicare patients was Doxycycline Hyclate, with 595 prescriptions and refills. In total Anwer Jaffri wrote 7,224 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Doxycycline Hyclate Generic | 595 | 641 | 266 | $6,626 |
| Levothyroxine Sodium Generic | 267 | 267 | 16 | $3,161 |
| Furosemide Generic | 225 | 225 | 22 | $2,406 |
| Cefpodoxime Proxetil Generic | 213 | 213 | 142 | $19K |
| Shingrix Varicella-Zoster Ge/As01b/Pf | 199 | 211 | 151 | $41K |
| Abrysvo Rsv Vacc, Pref A And Pref B/Pf | 166 | 166 | 163 | $50K |
| Daptomycin Generic | 164 | 164 | 23 | $67K |
| Eliquis Apixaban | 151 | 151 | 13 | $44K |
| Atorvastatin Calcium Generic | 148 | 148 | 24 | $2,567 |
| Jardiance Empagliflozin | 138 | 138 | Under 11 | $42K |
| Sertraline Hcl Generic | 115 | 115 | 21 | $1,586 |
| Dovato Dolutegravir Sodium/Lamivudine | 110 | 110 | Under 11 | $322K |
| Arexvy Rsvpref3 Antigen/As01e/Pf | 100 | 100 | 99 | $29K |
| Metoprolol Succinate Generic | 92 | 92 | 15 | $1,988 |
| Potassium Chloride Generic | 90 | 92 | 13 | $2,823 |
Brand drugs: 2,367 claims; generic drugs: 4,794 claims; opioid claims: 82.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Anwer Jaffri $2,539 ($2,539 in general payments such as food, travel and fees) from 13 companies. The largest payer was Gilead Sciences, Inc. with $766.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 10 | $766 |
| ViiV Healthcare Company GSK | 34 | $751 |
| Aimmune Therapeutics, Inc. | 10 | $299 |
| EMD Serono, Inc. MRK.DE | 6 | $153 |
| Paratek Pharmaceuticals, Inc. | 11 | $137 |
| Merck Sharp & Dohme LLC MRK | 6 | $115 |
| CSL Behring CSL.AX | 4 | $88.84 |
| Pfizer Inc. PFE | 3 | $58.15 |
| Cumberland Pharmaceuticals, Inc. CPIX | 1 | $52.32 |
| Insmed, Inc. INSM | 2 | $33.53 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.